In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D 3 as Cardio-protectant and Anti-cancer Agent
Anticancer Research · 2025
DOI: 10.21873/anticanres.17608 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Yesenia L Franco und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, U.S.A. Hauptthemen laut MEDLINE: Cholecalciferol, Doxorubicin, Myocytes, Cardiac, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: Doxorubicin (DOX) is a potent and widely used chemotherapeutic; however, DOX-induced cardiotoxicity (DIC) remains a major clinical challenge. This study evaluated the cardio-protective and cytotoxic activities of vitamin D3 in combination with DOX and as a single agent. MATERIALS AND METHODS: Immortalized human cardiomyocytes (AC16) and breast and liver cancer cells (JIMT-1, Huh-7) were exposed to DOX, vitamin D3, and their simultaneous (Sim) or sequential (Seq) combinations for 48 and 72 h. The maximum inhibitory effects (Imax) and concentrations leading to 50% of Imax (IC50) for each drug were estimated with Hill equation using Monolix2016R1 software. Combination indices (CI) for Sim and Seq were calculated using CompuSyn software. RESULTS: The concentration-effect relationships revealed that cardiomyocytes were more sensitive to DOX than cancer cells, with IC50 at 0.01 μM (AC16), 0.07 μM (Huh-7), and 0.125 μM (JIMT-1). Moreover, vitamin D3 concentrations maintained the baseline AC16 cell viability up to 10 μM, above which cardiomyocyte viability began to decline (IC50=34.5 μM). The anti-cancer action of vitamin D3 occurs at supra-physiological concentrations with IC50 at 22.8 μM (Huh-7) and 40.9 μM (JIMT-1). The CI analysis in cardiomyocytes revealed a time-dependent shift in drug interaction from antagonistic (CI>1, 48 h) towards synergistic (CI
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL, U.S.A.
- Merck & Co., Inc., Rahway, NJ, U.S.A. sb.manuscript.submission@gmail.com.
Zitieren
APA
Franco, Y. L., Mody, H., & Ait-Oudhia, S. (2025). In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D 3 as Cardio-protectant and Anti-cancer Agent. Anticancer Research. https://doi.org/10.21873/anticanres.17608
Vancouver
Franco YL, Mody H, Ait-Oudhia S. In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D 3 as Cardio-protectant and Anti-cancer Agent. Anticancer Research. 2025. doi:10.21873/anticanres.17608
BibTeX
@article{Franco2025,
author = {Franco, Yesenia L and Mody, Hardik and Ait-Oudhia, Sihem},
title = {In Vitro Evaluation of the Dual Pharmacological Action of Vitamin D 3 as Cardio-protectant and Anti-cancer Agent},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17608}
}
EUVIMED